Caspofungin disk diffusion breakpoints and quality control.

Journal of Clinical Microbiology
S D Brown, Maria M Traczewski

Abstract

Interpretive disk diffusion breakpoints for caspofungin are proposed by evaluating 762 isolates of Candida spp., representing 10 different species obtained as part of the caspofungin clinical trials. Standardized broth microdilution reference tests were compared to the zone diameters observed with 5-microg caspofungin disks produced by two different disk manufacturers. Disk diffusion breakpoints of >or=11 mm for susceptible are proposed. Compared to results from MIC testing, these zone diameters produced error rates that were <or=0.3% for all categories. In addition, an eight-laboratory disk diffusion quality control (QC) study was performed, and QC ranges are proposed for the four QC strains recommended by the CLSI.

References

Jul 1, 1997·Journal of Medical and Veterinary Mycology : Bi-monthly Publication of the International Society for Human and Animal Mycology·P W NelsonJ H Rex
Apr 19, 2000·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·J H RexJ E Edwards
Sep 2, 2000·Journal of Clinical Microbiology·A L BarryM G Rinaldi
Dec 31, 2003·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Peter G PappasUNKNOWN Infectious Diseases Society of America
Nov 25, 2004·Antimicrobial Agents and Chemotherapy·Donna M MacCallum, Frank C Odds
Mar 3, 2006·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Mikkel Krogh-MadsenJenny Dahl Knudsen
Mar 7, 2006·Journal of Clinical Microbiology·M A PfallerD J Diekema

❮ Previous
Next ❯

Citations

Mar 1, 2011·Drug Resistance Updates : Reviews and Commentaries in Antimicrobial and Anticancer Chemotherapy·M A PfallerUNKNOWN CLSI Subcommittee for Antifungal Testing
Jul 23, 2009·Expert Review of Anti-infective Therapy·Emilia CantónJavier Pemán
Jun 12, 2010·Expert Opinion on Pharmacotherapy·Varsha Moudgal, Jack Sobel
Apr 24, 2020·Expert Review of Anti-infective Therapy·Ludwig Knabl, Cornelia Lass-Flörl
May 1, 2020·Clinical Microbiology Reviews·Elizabeth L BerkowLuis Ostrosky-Zeichner

❮ Previous
Next ❯

Related Concepts

Related Feeds

Candidiasis

Candidiasis is a common fungal infection caused by Candida and it can affect many parts for the body including mucosal membranes as well as the gastrointestinal, urinary, and respiratory tracts. Here is the latest research.

Antifungals

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Candidiasis (ASM)

Candidiasis is a common fungal infection caused by Candida and it can affect many parts for the body including mucosal membranes as well as the gastrointestinal, urinary, and respiratory tracts. Here is the latest research.

Candida albicans

Candida albicans is an opportunistic, fungal pathogen of humans that frequently causes superficial infections of oral and vaginal mucosal surfaces of debilitated and susceptible individuals. Discover the latest research on Candida albicans here.

Antifungals (ASM)

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Related Papers

Drug Resistance Updates : Reviews and Commentaries in Antimicrobial and Anticancer Chemotherapy
David S Perlin
© 2022 Meta ULC. All rights reserved